Metabolic Blood Hormones in Young People With Electrocardiographic Signs of Ischemic Myocardial Changes

Aim    To study changes in blood concentrations of metabolic hormones and adipocytokines in people aged 25-44 years with electrocardiographic (ECG) signs of ischemic changes in the myocardium.
Material and methods This study was a part of a cross-sectional survey of a random sample of Novosibirsk population aged 25-44 years. The study included 1363 people divided into two groups: group 1, subjects with ECG signs of ischemic changes in the myocardium and group 2, subjects without ECG changes. Blood serum concentrations of adipocytokines and metabolic hormones were measured by multiplex assay on a Luminex MAGPIX flow-through fluorometer.
Results    The group with ECG signs of myocardial ischemia had higher blood concentrations of adiponectin, resistin, glucagon, and interleukin 6 (IL-6) than in the comparison group. A multivariate logistic regression analysis showed that the glucagon concentration was associated with the presence of ECG signs of myocardial ischemia (OR, 1.019; CI, 1.018-1.034; p=0.017).
Conclusion    In young people aged 25-44 years, higher blood concentrations of glucagon are associated with the presence of ECG signs of myocardial ischemia.

1. Ragino YI, Stakhneva EM, Polonskaya YV, Kashtanova EV. The Role of Secretory Activity Molecules of Visceral Adipocytes in Abdominal Obesity in the Development of Cardiovascular Disease: A Review. Biomolecules. 2020;10(3):374. DOI: 10.3390/biom10030374

2. Francisco V, Pino J, Gonzalez-Gay MA, Mera A, Lago F, Gómez R et al. Adipokines and inflammation: is it a question of weight? British Journal of Pharmacology. 2018;175(10):1569–79. DOI: 10.1111/bph.14181

3. Andreenko E.Yu., Yavelov I.S., Loukianov M.M., Vernohaeva A.N., Drapkina O.M., Boytsov S.A. Ischemic Heart Disease in Subjects of Young Age: Current State of the Problem: Prevalence and CardioVascular Risk Factors. Kardiologiia. 2018;58(10):53–8.

4. Neeland IJ, Ross R, Després J-P, Matsuzawa Y, Yamashita S, Shai I et al. Visceral and ectopic fat, atherosclerosis, and cardiometabolic disease: a position statement. The Lancet Diabetes & Endocrinology. 2019;7(9):715–25. DOI: 10.1016/S2213-8587(19)30084-1

5. Otelea MR, Streinu-Cercel A, Băicus C, Maria Nitescu M. The Adipokine Profile and the Cardiometabolic Risk in Non-Obese Young Adults. Balkan Medical Journal. 2019;36(3):155–61. DOI: 10.4274/balkanmedj.galenos.2018.2018.0789

6. Carbone S, Canada JM, Billingsley HE, Siddiqui MS, Elagizi A, Lavie CJ. Obesity paradox in cardiovascular disease: where do we stand? Vascular Health and Risk Management. 2019;15:89–100. DOI: 10.2147/VHRM.S168946

7. Wu Z-J, Cheng Y-J, Gu W-J, Aung LHH. Adiponectin is associated with increased mortality in patients with already established cardiovascular disease: A systematic review and meta-analysis. Metabolism. 2014;63(9):1157–66. DOI: 10.1016/j.metabol.2014.05.001

8. Adela R, Reddy PNC, Ghosh TS, Aggarwal S, Yadav AK, Das B et al. Serum protein signature of coronary artery disease in type 2 diabetes mellitus. Journal of Translational Medicine. 2019;17(1):17. DOI: 10.1186/s12967-018-1755-5

9. Yuxiang L, Fujiu K. Human Resistin and Cardiovascular Disease. International Heart Journal. 2020;61(3):421–3. DOI: 10.1536/ihj.20-221

10. Kalinina A.M., Shalnova S.A., Gambaryan M.G., Eganyan R.A., Muromtseva G.A., Bochkareva E.V. et al. Epidemiological methods for identifying the main chronic non-communicable diseases and risk factors during mass population surveys. Methodical guide. Edited by Prof. Boytsov S.A. - M.: GNICPM; 2015. - 96p. Av. at: https://gnicpm.ru/wp-content/uploads/2020/01/metodposobie_epid_metody_viyavleniya_hniz_pri_massovih_obsledovaniyah.pdf.

11. Kappelle PJWH, Dullaart RPF, van Beek AP, Hillege HL, Wolffenbuttel BHR. The plasma leptin/adiponectin ratio predicts first cardiovascular event in men: A prospective nested case–control study. European Journal of Internal Medicine. 2012;23(8):755–9. DOI: 10.1016/j.ejim.2012.06.013

12. Sierra-Johnson J, Romero-Corral A, Lopez-Jimenez F, Gami AS, Sert Kuniyoshi FH, Wolk R et al. Relation of Increased Leptin Concentrations to History of Myocardial Infarction and Stroke in the United States Population. The American Journal of Cardiology. 2007;100(2):234–9. DOI: 10.1016/j.amjcard.2007.02.088

13. Khoramipour K, Chamari K, Hekmatikar AA, Ziyaiyan A, Taherkhani S, Elguindy NM et al. Adiponectin: Structure, Physiological Functions, Role in Diseases, and Effects of Nutrition. Nutrients. 2021;13(4):1180. DOI: 10.3390/nu13041180

14. Zhao S, Kusminski CM, Scherer PE. Adiponectin, Leptin and Cardiovascular Disorders. Circulation Research. 2021;128(1):136–49. DOI: 10.1161/CIRCRESAHA.120.314458

15. Singh M, Bedi US, Singh PP, Arora R, Khosla S. Leptin and the clinical cardiovascular risk. International Journal of Cardiology. 2010;140(3):266–71. DOI: 10.1016/j.ijcard.2009.07.019

16. Markova T.N., Mishchenko N.K., Petina D.V. Adipocytokines: modern definition, classification and physiological role. Problems of Endocrinology. 2022;68(1):73–80.

17. Acquarone E, Monacelli F, Borghi R, Nencioni A, Odetti P. Resistin: A reappraisal. Mechanisms of Ageing and Development. 2019;178:46–63. DOI: 10.1016/j.mad.2019.01.004

18. Hivert M-F, Manning AK, McAteer JB, Dupuis J, Fox CS, Cupples LA et al. Association of Variants in RETN With Plasma Resistin Levels and Diabetes-Related Traits in the Framingham Offspring Study. Diabetes. 2009;58(3):750–6. DOI: 10.2337/db08-1339

19. Elkhattabi L, Morjane I, Charoute H, Amghar S, Bouafi H, Elkarhat Z et al. In Silico Analysis of Coding/Noncoding SNPs of Human RETN Gene and Characterization of Their Impact on Resistin Stability and Structure. Journal of Diabetes Research. 2019;2019:4951627. DOI: 10.1155/2019/4951627

20. Jamaluddin MS, Weakley SM, Yao Q, Chen C. Resistin: functional roles and therapeutic considerations for cardiovascular disease. British Journal of Pharmacology. 2012;165(3):622–32. DOI: 10.1111/j.1476-5381.2011.01369.x

21. Chu S, Ding W, Li K, Pang Y, Tang C. Plasma Resistin Associated With Myocardium Injury in Patients With Acute Coronary Syndrome. Circulation Journal. 2008;72(8):1249–53. DOI: 10.1253/circj.72.1249

22. Ohtsuki T, Satoh K, Shimizu T, Ikeda S, Kikuchi N, Satoh T et al. Identification of Adipsin as a Novel Prognostic Biomarker in Patients With Coronary Artery Disease. Journal of the American Heart Association. 2019;8(23):e013716. DOI: 10.1161/JAHA.119.013716

23. Petersen KM, Bøgevig S, Holst JJ, Knop FK, Christensen MB. Hemodynamic Effects of Glucagon: A Literature Review. The Journal of Clinical Endocrinology & Metabolism. 2018;103(5):1804–12. DOI: 10.1210/jc.2018-00050

24. Osaka N, Kushima H, Mori Y, Saito T, Hiromura M, Terasaki M et al. Anti-inflammatory and atheroprotective properties of glucagon. Diabetes and Vascular Disease Research. 2020;17(5):147916412096518. DOI: 10.1177/1479164120965183

25. Ng JCM, Schooling CM. Effect of Glucagon on Ischemic Heart Disease and Its Risk Factors: A Mendelian Randomization Study. The Journal of Clinical Endocrinology & Metabolism. 2020;105(8):dgaa259. DOI: 10.1210/clinem/dgaa259

26. Meier JJ. The role of incretin-based therapies in the management of type 2 diabetes mellitus: perspectives on the past, present and future. Diabetes mellitus. 2020;22(5):461–6. DOI: 10.14341/DM11493

27. Andreasen CR, Andersen A, Knop FK, Vilsbøll T. How glucagon-like peptide 1 receptor agonists work. Endocrine Connections. 2021;10(7):R200–12. DOI: 10.1530/EC-21-0130

28. Alkhezi OS, Alahmed AA, Alfayez OM, Alzuman OA, Almutairi AR, Almohammed OA. Comparative effectiveness of glucagon‐like peptide‐1 receptor agonists for the management of obesity in adults without diabetes: A network meta‐analysis of randomized clinical trials. Obesity Reviews. 2023;24(3):e13543. DOI: 10.1111/obr.13543

29. Htike ZZ, Zaccardi F, Papamargaritis D, Webb DR, Khunti K, Davies MJ. Efficacy and safety of glucagon‐like peptide‐1 receptor agonists in type 2 diabetes: A systematic review and mixed‐treatment comparison analysis. Diabetes, Obesity and Metabolism. 2017;19(4):524–36. DOI: 10.1111/dom.12849

30. Pedrosa MR, Franco DR, Gieremek HW, Vidal CM, Bronzeri F, De Cassia Rocha A et al. GLP-1 Agonist to Treat Obesity and Prevent Cardiovascular Disease: What Have We Achieved so Far? Current Atherosclerosis Reports. 2022;24(11):867–84. DOI: 10.1007/s11883-022-01062-2

31. Ma X, Liu Z, Ilyas I, Little PJ, Kamato D, Sahebka A et al. GLP-1 receptor agonists (GLP-1RAs): cardiovascular actions and therapeutic potential. International Journal of Biological Sciences. 2021;17(8):2050–68. DOI: 10.7150/ijbs.59965

32. Chen WR, Chen YD, Tian F, Yang N, Cheng LQ, Hu SY et al. Effects of Liraglutide on Reperfusion Injury in Patients With ST-Segment– Elevation Myocardial Infarction. Circulation: Cardiovascular Imaging. 2016;9(12):e005146. DOI: 10.1161/CIRCIMAGING.116.005146